Leadership

Michael Underhill is the founding CEO and CSO of Mesintel Therapeutics. Michael is also a Professor at the University of British Columbia, and has published > 90 papers on various aspects of fibroblast biology. He is an inventor on 8 foundational patents involving the manipulation of fibroblasts to affect disease, and served as the head of target identification and co-scientific director for the Centre for Drug Research and Development (CDRD, now adMare). Michael received his BSc and PhD from Western University, and carried out post-doctoral studies at Duke University.